<?xml version='1.0' encoding='utf-8'?>
<document id="25078948"><sentence text="&quot;Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183&quot;."><entity charOffset="106-112" id="DDI-PubMed.25078948.s1.e0" text="taxane" /></sentence><sentence text="BMS-275,183 is a novel oral C-4 methyl carbonate analogue of paclitaxel"><entity charOffset="28-48" id="DDI-PubMed.25078948.s2.e0" text="C-4 methyl carbonate" /><entity charOffset="61-71" id="DDI-PubMed.25078948.s2.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.25078948.s2.e0" e2="DDI-PubMed.25078948.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25078948.s2.e0" e2="DDI-PubMed.25078948.s2.e1" /></sentence><sentence text=" Recently, a drug-drug interaction between BMS-275,183 and benzimidazole proton pump inhibitors (PPIs) was suggested in clinical trials resulting in elevated drug exposure and toxicity"><entity charOffset="59-72" id="DDI-PubMed.25078948.s3.e0" text="benzimidazole" /></sentence><sentence text=" We explored whether the interaction takes place at the level of P-glycoprotein (Pgp, MDR1, ABCB1), Breast Cancer Resistance Protein (BCRP, ABCG2) and MRP2 (ABCC2) using in vitro and in vivo models" /><sentence text=" In vitro cell survival, drug accumulation, efflux and transport studies with BMS-275,183 were performed employing MDCKII (wild-type, MDR1, BCRP, MRP2) and LLCPK (wild-type and MDR1) cells" /><sentence text=" In vivo the pharmacokinetics and tissue distribution of BMS-275,183 after p" /><sentence text="o" /><sentence text=" and i" /><sentence text="v" /><sentence text=" administration were explored in Mdr1a/1b(-/-) and wild-type mice, in presence or absence of the PPI pantoprazole"><entity charOffset="101-113" id="DDI-PubMed.25078948.s10.e0" text="pantoprazole" /></sentence><sentence text=" Results In vitro, BMS-275,183 was found to be a good substrate for MDR1, a moderate substrate for MRP2 and not a substrate for BCRP" /><sentence text=" In vivo, oral bioavailability, plasma AUC0-6h and brain concentrations were significantly 1" /><sentence text="5-, 4-, and 2-fold increased, respectively, in Mdr1a/1b(-/-) compared with wild-type mice (p &lt; 0" /><sentence text="001)" /><sentence text=" However, oral co-administration of pantoprazole (40 mg/kg) did not alter the pharmacokinetics of BMS-275,183 in wild-type mice"><entity charOffset="36-48" id="DDI-PubMed.25078948.s15.e0" text="pantoprazole" /></sentence><sentence text=" Conclusions BMS-275,183 is efficiently transported by Pgp and to a lesser extent by MRP2 in vitro" /><sentence text=" Genetic deletion of Pgp significantly altered the pharmacokinetics and brain distribution of p" /><sentence text="o" /><sentence text=" and i" /><sentence text="v" /><sentence text=" administered BMS-275,183 in Mdr1a/1b-/- compared to wild-type mice" /><sentence text=" Oral co-administration of BMS-275,183 with pantoprazole did not affect the pharmacokinetics of BMS-275,183 in wild-type mice, suggesting no interaction with PPI at the dose employed"><entity charOffset="44-56" id="DDI-PubMed.25078948.s22.e0" text="pantoprazole" /></sentence><sentence text="" /></document>